Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

This article is part of the supplement: AIDS Vaccine 2009 .

Open AccessPoster presentation

P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors

J Binley1, T Wrin2, R Pantophlet3, P Phung2, ET Crooks1, A Lapedes4, N Taylor5, L Cavacini6, G Steigler7, R Kunert7, H Katinger7, C Petropoulos2, D Richman8, L Morris5, R Sutthent9 and DR Burton10

AIDS/Viral Immunology, Torrey Pines Institute, San Diego, CA, USA

MonoGramBio, San Francisco, CA, USA

Simon Fraser University, Vancouver, Canada

Los Alamos National Laboratory, Los Alamos, NM, USA

National Institute for Communicable Diseases, Johannesburg, South Africa

Beth Israel Medical Center, Boston, MA, USA

University of Agricultural Sciences, Vienna, Austria

University of California, San Diego, La Jolla, CA, USA

HIV Bioinformatic Center, Bangkok, Thailand

10  The Scripps Research Institute, La Jolla, CA, USA

corresponding author email

from AIDS Vaccine 2009
Paris, France. 19–22 October 2009

Retrovirology 2009, 6(Suppl 3):P31doi:10.1186/1742-4690-6-S3-P31

Published: 22 October 2009

First paragraph (this article has no abstract)

The genetic diversity of HIV-1, particularly in Env, is considered a major challenge for vaccine researchers, especially those attempting to elicit broadly neutralizing antibodies. Categorizing HIV strains into neutralization serotypes may help determine the requirements for maximal vaccine immune coverage. HIV is divided into clades, based on genetic relatedness, principally in Env. Investigations as to whether these clades might help to define neutralizing serotypes have so far mostly been confined to small studies, and have been hampered by the challenges of traditional PBMC-blast neutralization assays. The observation that some HIV+ plasmas neutralize viruses from several major clades hints of an undercurrent of conserved neutralization, but its potency relative to any clade-restricted activity is unknown. High throughput pseudovirus neutralization assays provide a way to investigate.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.